© 2021 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Biosimilars
An FDA First: Semglee Is Approved As An Interchangeable Biosimilar
July 29, 2021
FDA approval means that pharmacists can swap biosimilar Semglee, an insulin product, for brand-name Lantus, although state-level pharmacy rules may apply.
Vizient’s Outlook Report Is a Mixed Bag: Projected 2022 Drug Spend, White Bagging, Insulin Competition and COVID-19 Treatment. It’s All in There.
July 29, 2021
Wide ranging report covers a lot of ground. It sounds an optimistic note about biosimilars but is critical of white bagging.
The Generic, Biosimilar Medicine Industry Today and What it Can Become in The Next Decade
July 14, 2021
International Generic and Biosimilar Medicines Association recently released the report, "A Vision for the Global Generic and Biosimilar Medicines Industry,” covering the current global Generic and Biosimilar medicine industry, and released a vision of what the market will be in 2030 and how to achieve it.
When Humira Finally Faces Biosimilar Competition, Losses For AbbVie May Not Be As Steep As Expected, Say Analysts
July 14, 2021
Research note from SVB Leerink says revenue erosion once biosimilars hit the market in 2023 may be more gradual than some prior predictions.
Generic Drug Price Tags: Too High. And Too Low. Competition Can Help Create an In-Between.
July 13, 2021
Low prices and some gaming of regulations can drive out competitors and create monopolies that allow generic makers to jack up their prices. Experience has shown that it often takes multiple generics to achieve the promised-for downward pressure on prices.
Cigna Offers $500 Incentive for Switching to Biosimilars
July 08, 2021
Insurer also moves two approved biosimilars for Remicade, Avsola and Inflectra, to preferred status.
COVID-19 May Continue to Impact Healthcare Costs
February 01, 2021
Biosimilars may reduce healthcare costs.
While We Await Vaccine Progress, We Can Trust in Generic Drugs
February 01, 2021
Generic drugs account for 90% of the prescriptions filled in the United States. They are the backbone of healthcare providers’ treatment protocol and they are remarkably cost effective: despite being 90% of the prescriptions filled, generics account for only 20% of drug spending.
MHE’s Most-Read Oncology News in 2020
December 29, 2020
Drug and diagnostic approvals and biosimilars news were popular with readers.
Talking Biosimilars With OneOncology’s Dr. Jeff Patton
October 31, 2020
The leading community oncology practice partnership has been an early adopter of biosimilars, and a trouble-shooter for hurdles with payers.